Learn more about ALS
What is ALS?
Amyotrophic lateral sclerosis, also known as motor neuron disease or Lou Gehrig's disease, is a specific disease that causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common.
Most cases of ALS (about 90% to 95%) have no known cause and are known as sporadic ALS. However, both genetic and environmental factors are believed to be involved. The remaining 5% to 10% of cases have a genetic cause linked to a history of the disease in the family, and these are known as familial ALS.
What are the symptoms?
The onset of ALS can be so subtle that the symptoms are overlooked but gradually these symptoms develop into more obvious weakness or atrophy that may cause a physician to suspect ALS. Some of the early symptoms include:
fasciculations (muscle twitches) in the arm, leg, shoulder, or tongue
tight and stiff muscles (spasticity)
muscle weakness affecting an arm, a leg, neck, or diaphragm.
slurred and nasal speech
difficulty chewing or swallowing.
For many individuals, the first sign of ALS may appear in the hand or arm as they experience difficulty with simple tasks such as buttoning a shirt, writing, or turning a key in a lock. In other cases, symptoms initially affect one of the legs, and people experience awkwardness when walking or running or they notice that they are tripping or stumbling more often.
When symptoms begin in the arms or legs, it is referred to as “limb onset” ALS. Other individuals first notice speech or swallowing problems, termed “bulbar onset” ALS. (MORE Info Below)
How does BodyScience treat ALS?
Introducing BodyScience’s new Mito E program and our next generation MyoRepair program. The BodyScience Mito E programs combine targeted therapies designed to restore Mitochondrial Efficiency (Mito E) by addressing underlying mitochondrial-energy-scavengers like viruses, mold, heavy metals, and chemicals while simultaneously building and restoring muscle with MyoRepair.
Our mission is to incorporate new technologies that have been shown clinically to work in people with neurodegenerative disorders and pair them in a way to get the best synergistic effect. Treatments are individualized using our unique patient classification system which connects your unique symptom onset and progression with your specific exposures to determine the combination of treatments best suited for you. We have been seeing a whole new level of improvement in the pALS who have come for three weeks or more.
MyoRepair is a technology that we developed for pALS and others with muscle atrophy disorders including Multiple Sclerosis (MS) and some forms of Muscular Dystrophy (MD). The amino acid formulation commonly referred to as GAC is customized for each patient in that the type and percent of each amino acid as well as the pH are individualized to ensure the best outcomes.
Lingual Lift is a targeted treatment developed at BodyScience to restore strength and function in the tongue and adjacent muscles for improved speaking, swallowing and chewing.
BodyScience Mito E (i.e. Mitochondrial Efficiency)
BodyScience Mito E programs are designed to work synergistically with MyoRepair. Building muscle and addressing the root cause of neurodegenerative diseases at the cellular level are fundamental for addressing these disorders. Unlocking the mitochondria is the key pathway in these conditions. When these two programs are combined the results are significantly more effective and longer lasting. Due to the intense nature of these treatments, both the Myorepair and Mito E programs are administered separately, each for a week at a time. Rescue injections can however be added to the Mito E programs. The recommended minimum treatment time for optimal and long lasting results is 3-4 weeks.
The are 4 different Mito E programs: each designed to meet your specific needs.
1 - BodyScience Mito E General Program – for people with neuromuscular degenerative disease. This cellular level treatment is targeted toward mitochondrial efficiency and restoring intra-cellular health. It is comprised of a Regulatory T-cell support, targeted neuroprotection therapy, mitochondrial optimizers and neuro-antioxidants.
2 - BodyScience Mito E for Mold, Lyme, Viruses and other infectious agents – if you have ever been diagnosed with or exposed to mold, yeast (ie Candida), lyme disease, viruses such as EMB, CMV, HSV, or Parvo this program starts with a comprehensive consultation individualized to address your specific infectious burden and devise a treatment plan which would best work for you.
3- BodyScience Mito-E for Heavy Metals – This is the program for individuals who have tested positive for or have been exposed to heavy metals. This protocol is also for the those who have worked in the metal or mining industry, lived close to coal mining burning facilities, used coal fireplaces extensively, or consumed foods high in metals such as fish.
4- BodyScience Mito-E for Chemical and/or Environmental Exposures – This is the program for individuals who have tested positive for or have been exposed to toxic chemicals such as organophosphates, glyphosphates, fungicides, herbicides or pesticides. It is the protocol for those who have worked in agriculture, lived in industrial zones or areas known to have high levels of contamination such as coastal regions.
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis or ALS, it is a progressive neurodegenerative disease, It mainly affects the nerve cells that control all the voluntary movement of the body including walking, chewing, moving, daily tasks, and others, ALS affects all. Amyotrophic Lateral Sclerosis symptoms can get worse with the time and unable body to take voluntary actions on its own. Amyotrophic lateral Sclerosis is the term of the disease derived from the Greek language, where “A” refers to “NO”, “Myo” means “Muscles”, and “Trophic” refers to the nourishment, hence it means “No Muscles Nourishment”. However Lateral term refers to the spinal cord area, and Sclerosis means hardening or scarring of an area. This disease is also known as Motor Neuron Disease and Lou Gehrig’s disease. When a muscles fail to get the nourishment they require to carry the functions, they atrophy.
Amyotrophic Lateral Sclerosis (ALS) is a deleterious disease and is generally characterized into: Lower Motor Neuron Disease (this affects the nerves that are coming from the brainstem and spinal cord) and Upper Motor Neuron Disease (this affects nerves in the brain specifically). In both cases, it affects motor neurons. It is damaging and fatal. The lifespan of the individual is short but after an ALS treatment, patients can survive more than 20 years. Depending on the characterization of the disease, each patient shows variable Amyotrophic lateral sclerosis symptoms. With time, when the disease gets progression, it affects more number of the nerve cells which is difficult to reserve, the muscles get weaker gradually after the onset of Amyotrophic Lateral Sclerosis (ALS), they lose their function and the limbs get thinner and fragile. Over time, if left unattended, the muscles can become spastic which leads to the wider muscles’ mass of different parts of the body.
Amyotrophic Lateral sclerosis disease (ALS) is defined as the death of the Motor neurons that carrying out voluntary movements. Although the cause of the onset of this fatal disease is not understood completely but mainly the cause is familial, almost 5-10% of the prevalence is hereditary. Current studies are exploring the conclusive reason behind amyotrophic lateral sclerosis and have explored that there is the complex interaction between genetic and environmental factors. However, we have got to conclude the factors associated with the onset of Amyotrophic lateral sclerosis which includes Aging factors which exacerbate the functioning of most body cells, Poor diet, Hormonal imbalance, impaired Gut Health, Cytoskeleton Protein Defects, Free Radical Injury, Genes Defect, Apoptosis, Viral Infection, Mitochondrial dysfunction, poor autoimmune mechanism, and accumulation of the protein. Prevalence before the age of 65 is more common in men than women.
Amyotrophic Lateral sclerosis (ALS) snatches the ability to control or initial the movement from the brain. Motor neurons, from brain are extended to the spinal cords, and to the rest of the body muscles. With ASL, patients may not be able to speak, breathe, eat, and talk. ASL, however, doesn’t affect sensory or other neurons. The body is still capable to receive senses but could respond back.
Types of ASL include Familial and Sporadic ASL. While the most common ASL that has affect almost 90% of the cases in USA is Sporadic ASL and the rest are due to the familial Amyotrophic lateral Sclerosis. Familial ASL is inherited, with the disease, offspring also inherit gene mutation on Chromosome 9 open reading frame 72, and the same mutation is also associated with frontal-temporal lobes atrophy that results in dementia. If offspring are not getting ASL they may receive gene mutation and show the signs frontal-temporal lobes atrophy only if the parents have mutated gene.